Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019043059) COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-EGFR ANTIBODIES
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/043059 International Application No.: PCT/EP2018/073243
Publication Date: 07.03.2019 International Filing Date: 29.08.2018
IPC:
C12Q 1/6886 (2018.01) ,C07K 16/28 (2006.01) ,C07K 16/30 (2006.01) ,A61P 35/00 (2006.01)
[IPC code unknown for C12Q 1/6886]
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
SYMPHOGEN A/S [DK/DK]; Pederstrupvej 93 2750 Ballerup, DK
Inventors:
KRAGH, Michael; DK
POULSEN, Thomas Tuxen; DK
DING, Cliff; DK
HORAK, Ivan David; DK
Agent:
POHLMAN, Sandra; DE
Priority Data:
62/552,12530.08.2017US
Title (EN) COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-EGFR ANTIBODIES
(FR) COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DU CANCER PAR DES ANTICORPS ANTI-EGFR
Abstract:
(EN) The present invention provides methods and uses of anti-EGFR antibody compositions for treatment of cancers that are negative for certain mutations in RAS, BRAF, and the EGFR extracellular domain and are resistant to other anti-EGFR therapies.
(FR) La présente invention concerne des procédés et des utilisations de compositions d'anticorps anti-EGFR pour le traitement de cancers qui sont négatifs pour certaines mutations dans RAS, BRAF et le domaine extracellulaire d'EGFR et qui sont résistants à d'autres thérapies anti-EGFR.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)